STAT+: BioNTech founders to depart, form new mRNA-focused company

Ugur Sahin and Özlem Türeci, the co-founders of BioNTech, are departing from the company to establish a new firm focused on mRNA technology. This decision marks a significant shift for the couple, who played a pivotal role in developing the Covid-19 vaccine through BioNTech. Their new venture will concentrate on advancing mRNA applications beyond the current scope of Covid-19 vaccines, although specific details about the new company's goals and projects have not been disclosed. BioNTech has been recognized for its contributions to the global response to the Covid-19 pandemic, particularly through its collaboration with Pfizer to produce one of the first vaccines authorized for emergency use. The departure of Sahin and Türeci raises questions about the future direction of BioNTech, especially as the company navigates the post-pandemic landscape and seeks to expand its portfolio of products and research initiatives. The news of their departure was reported by multiple sources, including Stat News, which highlighted the significance of their contributions to the biotech industry. The couple's expertise in mRNA technology has positioned them as leaders in the field, and their new company is anticipated to continue exploring innovative applications of this technology. As they transition from BioNTech, Sahin and Türeci's move reflects a broader trend in the biotech sector, where founders and leaders often seek to pursue new opportunities and challenges after achieving significant milestones in their original companies.